Figure 10. Oral Valganciclovir versus Intravenous Ganciclovir for Patients with Newly Diagnosed Cytomegalovirus Retinitis

Figure 10. Oral Valganciclovir versus Intravenous Ganciclovir for Patients with Newly Diagnosed Cytomegalovirus Retinitis

In this randomized trial, HIV-infected patients with newly diagnosed cytomegalovirus retinitis received induction therapy with either (1) oral valganciclovir 900 mg bid x 21 days, followed by 900 mg once daily or (2) intravenous ganciclovir 5 mg/kg bid x 21 days, followed by 5 mg/kg once daily. After 28 days, all patients received oral valganciclovir 900 mg once daily. The graph represents disease progression in the first 28 days: 7 (9.9%) of 71 in the oral valganciclovir group and 7 (10.0%) in the intravenous ganciclovir group.  After 28 days, all patients received oral valganciclovir 900 mg once daily. The graph represents progression of cytomegalovirus retinitis during the first four weeks.

This figure is based on data from Martin DF, Sierra-Madero J, Walmsley S, et al.  A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.  N Engl J Med. 2002;346:1119-26.

[Close Window]

From: HIV Web Study <www.hivwebstudy.org>
© 2006-11 University of Washington